Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

2.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.5K
Enzyme Inhibition01:30

Enzyme Inhibition

90.3K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
90.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health inequalities in enrolment and completion of pulmonary rehabilitation: analysis of >88 000 individuals with COPD from a National Respiratory Audit Programme.

Thorax·2026
Same author

Ester Prodrug NLRP3 Inflammasome Inhibitor NT-0796 is Brain Active due to Activation by Local Expression of Carboxylesterase-1.

ACS chemical neuroscience·2026
Same author

Reducing HIV incidence and mortality: two sides of the same coin in the approach to ending AIDS.

The lancet. HIV·2025
Same author

How to culturally adapt the pulmonary rehabilitation programme for people living with COPD in Sri Lanka: a qualitative study.

BMJ open respiratory research·2025
Same author

The ester-containing prodrug NT-0796 enhances delivery of the NLRP3 inflammasome inhibitor NDT-19795 to monocytic cells expressing carboxylesterase-1.

Biochemical pharmacology·2024
Same author

Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1<i>H</i>-pyrazol-4-yl)({[(2<i>S</i>)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework.

ACS pharmacology & translational science·2024

Related Experiment Video

Updated: Dec 21, 2025

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions
10:24

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions

Published on: June 11, 2015

11.1K

Comparison of Inhibitor and Substrate Selectivity between Rodent and Human Vascular Adhesion Protein-1.

Ryo Kubota1, Michael J Reid1, Kuo Lee Lieu1

  • 1Acucela Inc., 818 Stewart St., Suite 1110, Seattle, WA 98101, USA.

Mediators of Inflammation
|May 16, 2020
PubMed
Summary

Vascular adhesion protein-1 (VAP-1) enzyme activity differs across species. Understanding these differences in VAP-1 oxidative deamination is crucial for selecting appropriate animal models in anti-inflammatory drug development.

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

835
Titration ELISA as a Method to Determine the Dissociation Constant of Receptor Ligand Interaction
12:38

Titration ELISA as a Method to Determine the Dissociation Constant of Receptor Ligand Interaction

Published on: February 15, 2018

20.5K

Related Experiment Videos

Last Updated: Dec 21, 2025

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions
10:24

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions

Published on: June 11, 2015

11.1K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

835
Titration ELISA as a Method to Determine the Dissociation Constant of Receptor Ligand Interaction
12:38

Titration ELISA as a Method to Determine the Dissociation Constant of Receptor Ligand Interaction

Published on: February 15, 2018

20.5K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • Vascular adhesion protein-1 (VAP-1) is an amine oxidase involved in inflammation.
  • Inhibiting VAP-1's oxidative deamination is a therapeutic target for anti-inflammatory drugs.
  • Rodent VAP-1 was predicted to have a narrower, more hydrophilic active site than human VAP-1.

Purpose of the Study:

  • To compare the enzyme kinetics and inhibitor sensitivity of recombinant mouse, rat, and human VAP-1.
  • To evaluate the suitability of different VAP-1 variants for preclinical anti-inflammatory studies.

Main Methods:

  • An optimized in vitro oxidative deamination fluorescence assay using benzylamine (BA) was employed.
  • The inhibition of five known VAP-1 inhibitors was tested across mouse, rat, and human VAP-1.
  • Michaelis-Menten kinetics were determined for BA, phenylethylamine, and tyramine.

Main Results:

  • Human VAP-1 showed higher sensitivity to semicarbazide but lower sensitivity to hydralazine and LJP-1207 compared to rodent VAP-1.
  • No significant differences in sensitivity were observed for hydrophobic inhibitors (compound 35c, PXS-4728A) between species.
  • Rat VAP-1 exhibited the highest affinity for all tested substrates, while mouse VAP-1 showed intermediate affinity for BA and phenylethylamine.

Conclusions:

  • Species-specific differences in VAP-1 active site structure influence substrate and inhibitor binding.
  • Rat VAP-1 demonstrates distinct kinetic properties compared to mouse and human VAP-1.
  • These findings highlight the importance of considering VAP-1 species differences in preclinical anti-inflammatory research.